June 20th 2025
In a context of critical financial situation, CARMAT launches a donation campaign open to all to contribute to its funding and continuation of its activities
• Risk of insolvency as early as end of June 2025
• Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO’s message, click here
Paris, June 20, 2025 – 6:30 pm CEST
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission.
Critical financial situation and risk of insolvency at the end of June 2025
In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025.
The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, and an additional €4.5 million by the end of July 2025.
Despite efforts that are still ongoing, the Company has not yet been able to secure the financing required to continue its operations.
Launch of a donation campaign
Against this backdrop, and while continuing its efforts to raise funds, particularly through potential capital increases, CARMAT is today launching a donation campaign open to all. This initiative aims to allow individuals and organizations who support CARMAT’s mission and wish to contribute to the continuity of its operations to do so.
Practical information on the donation campaign
The campaign opens on Friday, June 20, 2025.
Donations can only be made via the onparticipe.fr platform (available on this link). Should they experience issues, donors are invited to contact CARMAT at the following email address: donor@carmatsas.com
Main risks associated with donations
Potential donors’ attention is drawn to the fact that donations made as part of this campaign are non-refundable and do not entail any equity stake in the Company. Donors will therefore not become creditors or shareholders of CARMAT through their donation.
Donors should also be aware that there is no guarantee that the donations received as part as this campaign, even in combination with any potential capital increases or other financing solutions that the Company could secure, will be sufficient to prevent a default at the end of June 2025 or beyond. As such, a default of the Company remains possible, even in the very short term.
Furthermore, donations made in the context of this campaign do not entitle donors to any tax benefits of any kind.
CARMAT, one of the most innovative French medtech companies in the world
Stéphane Piat, Chief Executive Officer of CARMAT, concludes: “After 30 years of research and with 120 patients treated, CARMAT’s artificial heart heart is now the most advanced artificial heart in the world and the most credible solution to address the major challenge of advanced heart failure. This condition is currently the world’s leading cause of death. As of today, heart transplantation remains the gold standard treatment, but human donor hearts are unfortunately not available in sufficient numbers, leaving thousands of patients without any solution every year.
CARMAT’s heart is therefore absolutely essential to fight this growing health crisis and bring hope to patients and their families.
In order to continue its mission, CARMAT urgently needs €3.5 million by the end of June 2025, and approximately €35 million over the next 12 months. Failing that, we will most likely be forced to cease operations.
Despite our best efforts in a highly deteriorated environment, we have not yet been able to secure the financing required to continue our mission. This is why we are today calling on everyone’s generosity to help CARMAT continue saving lives.”